Drug Farm

, dba Drug Farm, is a biotechnology company developing first-in-class drugs for immunological diseases using its mice genetics platform and AI technologies., a Chair Professor of Genetics and Vice President of Westlake University and Adjunct Professor of Genetics at Yale University. Drug Farm develops multiple first-in-class drugs pipelines of different stages for the treatment of immunological diseases such as DF-006, an oral ALPK1 agonist that effectively activates hepatic innate immunity, and DF-003, an oral ALPK1 kinase inhibitor that targets the treatment of renal disease, cardiovascular disease, and the rare ophthalmic genetic disease ROSAH. The company's R&D relies on its two major platforms, IDInVivo? that uses piggyBac transposon mutagenesis to generate a library of genetic mutations in mice, and MedChem5, a platform for drug molecule design using deep learning technologies. The company generates revenue from developing drugs for the treatment of immunological diseases.

1. Series D

   Jul 13, 2026

   Amount

   $55M

   Investors

   Locked

2. Series C

   May 16, 2023

   Amount

   $27M

   Investors

   Locked

3. Series A

   Feb 10, 2021

   Amount

   $56M

   Investors

   Locked